• 1
    Oxman TE. Antidepressants and cognitive impairment in the elderly. J Clin Psychiatry 1996; 57(Suppl 5): 3844.
  • 2
    Gray SL, Lai KV, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21: 10122.
  • 3
    Moore AR, O'Keeffe ST. Drug-induced cognitive impairment in the elderly. Drugs Aging 1999; 15: 1528.
  • 4
    Lagnaoui R, Begaud B, Moore N et al. Benzodiazepine use and risk of dementia: a nested case–control study. J Clin Epidemiol 2002; 55: 3148.
  • 5
    Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th edn. Edinburgh: Churchill Livingstone, 2003.
  • 6
    Bartus RT, Dean RL 3rd, Beer B, Lippa AS. The cholinergic hypothesis of geriatric memory dysfunction. Science 1982; 217: 40814.
  • 7
    Feinberg M. The problems of anticholinergic adverse effects in older patients. Drugs Aging 1993; 3: 33548.
  • 8
    Molchan SE, Martinez RA, Hill JL et al. Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. Brain Res Brain Res Rev 1992; 17: 21526.
  • 9
    Ray PG, Meador KJ, Loring DW, Zamrini EW, Yang XH, Buccafusco JJ. Central anticholinergic hypersensitivity in aging. J Geriatr Psychiatry Neurol 1992; 5: 727.
  • 10
    Beers MH. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997; 157: 15316.
  • 11
    Fick DM, Cooper JW, Wade WE, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003; 163: 271624.
  • 12
    Peters NL. Snipping the thread of life. Antimuscarinic side effects of medications in the elderly. Arch Intern Med 1989; 149: 241420.
  • 13
    Rochon PA, Gurwitz JH. Drug therapy. Lancet 1995; 346: 326.
  • 14
    Dartigues JF, Gagnon M, Barberger-Gateau P et al. The Paquid epidemiological program on brain ageing. Neuroepidemiology 1992; 11 (Suppl. 1): 1418.
  • 15
    Fuhrer R, Rouillon F. La version française de l’échelle CES-D (Center for Epidemiologic Studies-Depression Scale). Description et traduction de l’échelle d’auto-évaluation. Psychiatr Psychobiol 1989; 4: 1636.
  • 16
    Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 18998.
  • 17
    Benton A. Manuel pour l’Application du Test de Rétention Visuelle. Applications Cliniques et Expérimentales. Paris: Centre de Psychologie Appliquée, 1965.
  • 18
    Isaacs B, Kennie AT. The Set test as an aid to the detection of dementia in old people. Br J Psychiatry 1973; 123: 46770.
  • 19
    American Pyschiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 3rd edn, rev (DSM III-R). Washington, DC: American Psychiatric Association, 1987.
  • 20
    McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34: 93944.
  • 21
    Ganguli M, Belle S, Ratcliff G et al. Sensitivity and specificity for dementia of population-based criteria for cognitive impairment: the MoVIES project. J Gerontol 1993; 48: M15261.
  • 22
    Mulsant BH, Pollock BG, Kirshner M, Shen C, Dodge H, Ganguli M. Serum anticholinergic activity in a community-based sample of older adults: relationship with cognitive performance. Arch General Psychiatry 2003; 60: 198203.
  • 23
    Dartigues JF, Commenges D, Letenneur D et al. Cognitive predictors of dementia in elderly community residents. Neuroepidemiology 1997; 16: 2939.
  • 24
    Caine ED, Weingartner H, Ludlow CL, Cudahy EA, Wehry S. Qualitative analysis of scopolamine-induced amnesia. Psychopharmacology (Berl) 1981; 74: 7480.
  • 25
    Beatty WW, Butters N, Janowsky DS. Patterns of memory failure after scopolamine treatment: implications for cholinergic hypotheses of dementia. Behav Neural Biol 1986; 45: 196211.
  • 26
    Flicker C, Serby M, Ferris SH. Scopolamine effects on memory, language, visuospatial praxis and psychomotor speed. Psychopharmacology (Berl) 1990; 100: 24350.
  • 27
    Emeriau JP, Fourrier A, Dartigues JF, Begaud B. Drug prescriptions for the elderly. Bull Acad Natl Med 1998; 182: 141929.
  • 28
    McEvoy JP, McCue M, Spring B, Mohs RC, Lavori PW, Farr RM. Effects of amantadine and trihexyphenidyl on memory in elderly normal volunteers. Am J Psychiatry 1987; 144: 5737.
  • 29
    Katz IR, Sands LP, Bilker W, DiFilippo S, Boyce A, D’Angelo K. Identification of medications that cause cognitive impairment in older people: the case of oxybutynin chloride. J Am Geriatr Soc 1998; 46: 813.
  • 30
    Agostini JV, Leo-Summers LS, Inouye SK. Cognitive and other adverse effects of diphenhydramine use in hospitalized older patients. Arch Intern Med 2001; 161: 20917.
  • 31
    Basu R, Dodge H, Stoehr GP, Ganguli M. Sedative-hypnotic use of diphenhydramine in a rural, older adult, community-based cohort: effects on cognition. Am J Geriatr Psychiatry 2003; 11: 20513.
  • 32
    Marcantonio ER, Juarez G, Goldman L et al. The relationship of postoperative delirium with psychoactive medications. JAMA 1994; 272: 151822.
  • 33
    Inouye SK, Charpentier PA. Precipitating factors for delirium in hospitalized elderly persons. Predictive model and interrelationship with baseline vulnerability. JAMA 1996; 275: 8527.
  • 34
    Han L, McCusker J, Cole M, Abrahamowicz M, Primeau F, Elie M. Use of medications with anticholinergic effect predicts clinical severity of delirium symptoms in older medical inpatients. Arch Intern Med 2001; 161: 1099105.
  • 35
    Tune L, Coyle JT. Serum levels of anticholinergic drugs in treatment of acute extrapyramidal side effects. Arch General Psychiatry 1980; 37: 2937.
  • 36
    Tune L, Coyle JT. Acute extrapyramidal side effects: serum levels of neuroleptics and anticholinergics. Psychopharmacology (Berl) 1981; 75: 915.
  • 37
    Tune L, Strauss ME, Lew MF, Breitlinger E, Coyle JT. Serum levels of anticholinergic drugs and impaired recent memory in chronic schizophrenic patients. Am J Psychiatry 1982; 139: 14602.
  • 38
    Miller PS, Richardson JS, Jyu CA, Lemay JS, Hiscock M, Keegan DL. Association of low serum anticholinergic levels and cognitive impairment in elderly presurgical patients. Am J Psychiatry 1988; 145: 3425.
  • 39
    Thienhaus OJ, Allen A, Bennett JA, Chopra YM, Zemlan FP. Anticholinergic serum levels and cognitive performance. Eur Arch Psychiatry Clin Neurosci 1990; 240: 2833.
  • 40
    Tollefson GD, Montague-Clouse J, Lancaster SP. The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population. J Neuropsychiatry Clin Neurosci 1991; 3: 31419.
  • 41
    Mach JR Jr, Dysken MW, Kuskowski M, Richelson E, Holden L, Jilk KM. Serum anticholinergic activity in hospitalized older persons with delirium: a preliminary study. J Am Geriatr Soc 1995; 43: 4915.
  • 42
    Flacker JM, Cummings V, Mach JR Jr, Bettin K, Kiely DK, Wei J. The association of serum anticholinergic activity with delirium in elderly medical patients. Am J Geriatr Psychiatry 1998; 6: 3141.
  • 43
    Tune L. Serum anticholinergic activity levels and delirium in the elderly. Semin Clin Neuropsychiatry 2000; 5: 14953.